IMMUNOVANT, INC.— Sankey Diagram

Quarterly mode · period ending 2024-03-31 · SEC EDGAR

ComparingFY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)
Revenue
$25M
↑+229.2% +$17Mvs FY2023 (Q1+Q2+Q3+Q4)
Gross Profit
$25M
↑+229.2% +$17Mvs FY2023 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2024 (Q1+Q2+Q3+Q4)FY2023 (Q1+Q2+Q3+Q4)
Revenue$25M$8M
COGS$0$0
Gross Profit$25M$8M
R&D$213M$160M
SG&A$0$0
D&A$231K$193K
Other OpEx$0$0
Operating Income$0$0
Interest Exp.$0$0
Other Non-Op$0$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · IMVT · Comparing FY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)